Advertisement

Antibodies to human papillomavirus 16 L1 virus-like particles as an independent prognostic marker in cervical cancer

      Abstract

      Objective: Infection with high-risk human papillomavirus (HPV) types such as HPV-16 is a major risk factor for the development of cervical cancer. HPV-16 capsid antibodies are detectable in approximately 50% of patients with HPV-16 DNA-positive cervical cancer. We investigated the prognostic significance of HPV capsid antibodies for survival in patients with cervical cancer in comparison with conventional clinicopathologic features such as staging, histologic grading, histology, age, and treatment modality. Study design: Serum samples from 68 patients with cervical cancer and 65 healthy female control subjects were analyzed by enzyme-linked immunosorbent assay for HPV-specific immunoglobulin G (IgG) antibodies to baculovirus expressed HPV-6, HPV-11, HPV-16, and HPV-18 L1 virus-like particles (VLPs). Results: HPV-16 L1 IgG antibodies were detectable in 6 of 65 (9%) of the control subjects and in 19 of 68 (28%) of the patients with cervical cancer (P = .007). In the subgroup of patients with HPV-16 DNA-positive cervical cancer (comprising 50% of the investigated samples), HPV-16 L1 antibodies were detected in 40%. HPV-16 L1 seropositivity was in univariate and multivariate analysis in addition to International Federation of Gynecology and Obstetrics stage, the only independent positive prognostic factor for overall survival (P = .01). Conclusion: Antibodies to HPV-16 L1 were found to be an independent prognostic factor for overall survival in patients with cervical cancer. Thus, HPV-16 infection may be involved not only in oncogenesis but also in tumor development and behavior. (Am J Obstet Gynecol 2002;186:705-11.)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Parkin DM
        • Pisani P
        • Ferlay J
        Estimates of the worldwide incidence of 25 major cancers in 1990.
        Int J Cancer. 1999; 80: 827-841
        • Bosch FX
        • Manos MM
        • Munoz N
        • Sherman M
        • Jansen AM
        • Peto J
        • et al.
        Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.
        J Natl Cancer Inst. 1995; 87: 796-802
        • Lombard I
        • Vincent-Salomon A
        • Validire P
        • Zafrani B
        • de la RA
        • Clough K
        • et al.
        Human papillomavirus genotype as a major determinant of the course of cervical cancer.
        J Clin Oncol. 1998; 16: 2613-2619
        • Viladiu P
        • Bosch FX
        • Castellsague X
        • Munoz N
        • Escriba JM
        • Hamsikova E
        • et al.
        Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer.
        J Clin Oncol. 1997; 15: 610-619
        • Vousden KH
        Human papillomaviruses and cervical carcinoma.
        Cancer Cells. 1989; 1: 43-50
        • Vonka V
        • Hamsikova E
        • Kanka J
        • Ludvikova V
        • Sapp M
        • Smahel M
        Prospective study on cervical neoplasia, IV: presence of HPV antibodies.
        Int J Cancer. 1999; 80: 365-368
        • Park JS
        • Park DC
        • Kim CJ
        • Ahn HK
        • Um SJ
        • Park SN
        • et al.
        HPV-16-related proteins as the serologic markers in cervical neoplasia.
        Gynecol Oncol. 1998; 69: 47-55
        • Viscidi RP
        • Sun Y
        • Tsuzaki B
        • Bosch FX
        • Munoz N
        • Shah KV
        Serologic response in human papillomavirus-associated invasive cervical cancer.
        Int J Cancer. 1993; 55: 780-784
        • Christensen ND
        • Dillner J
        • Eklund C
        • Carter JJ
        • Wipf GC
        • Reed CA
        • et al.
        Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies.
        Virology. 1996; 223: 174-184
        • Christensen ND
        • Hopfl R
        • DiAngelo SL
        • Cladel NM
        • Patrick SD
        • Welsh PA
        • et al.
        Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies.
        J Gen Virol. 1994; 75: 2271-2276
        • Heim K
        • Christensen ND
        • Hoepfl R
        • Wartusch B
        • Pinzger G
        • Zeimet A
        • et al.
        Serum IgG, IgM, and IgA reactivity to human papillomavirus types 11 and 6 virus-like particles in different gynecologic patient groups.
        J Infect Dis. 1995; 172: 395-402
        • Wideroff L
        • Schiffman MH
        • Nonnenmacher B
        • Hubbert N
        • Kirnbauer R
        • Greer CE
        • et al.
        Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia.
        J Infect Dis. 1995; 172: 1425-1430
        • de Gruijl TD
        • Bontkes HJ
        • Walboomers JM
        • Schiller JT
        • Stukart MJ
        • Groot BS
        • et al.
        Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia.
        J Natl Cancer Inst. 1997; 89: 630-638
        • Lehtinen M
        • Dillner J
        • Knekt P
        • Luostarinen T
        • Aromaa A
        • Kirnbauer R
        • et al.
        Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study.
        BMJ. 1996; 312: 537-539
        • Christensen ND
        • Reed CA
        • Cladel NM
        • Hall K
        • Leiserowitz GS
        Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6.
        Virology. 1996; 224: 477-486
        • Roda Husman AM
        • Walboomers JM
        • van den Brule AJ
        • Meijer CJ
        • Snijders PJ
        The use of general primers GP5 and GP6 elongated at their 3` ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR.
        J Gen Virol. 1995; 76: 1057-1062
        • Kwok S
        Procedures to minimize PCR-product carry-over.
        in: PCR protocols-a guide to methods and applications. : Academic Press, San Diego1990: 142-145
        • Nonnenmacher B
        • Hubbert NL
        • Kirnbauer R
        • Shah KV
        • Munoz N
        • Bosch FX
        • et al.
        Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain.
        J Infect Dis. 1995; 172: 19-24
        • Petter A
        • Heim K
        • Guger M
        • Ciresa-Ko Nig A
        • Christensen N
        • Sarcletti M
        • et al.
        Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women.
        J Gen Virol. 2000; 81: 701-708
        • Lin YL
        • Borenstein LA
        • Selvakumar R
        • Ahmed R
        • Wettstein FO
        Progression from papilloma to carcinoma is accompanied by changes in antibody response to papillomavirus proteins.
        J Virol. 1993; 67: 382-389
        • Durst M
        • Kleinheinz A
        • Hotz M
        • Gissman L
        The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumors.
        J Gen Virol. 1985; 66: 1515-1522
        • Pirami L
        • Giache V
        • Becciolini A
        Analysis of HPV 16, 18, 31, and 35 DNA in pre-invasive and invasive lesions of the uterine cervix.
        J Clin Pathol. 1997; 50: 600-604
        • Stoler MH
        • Rhodes CR
        • Whitbeck A
        • Wolinsky SM
        • Chow LT
        • Broker TR
        Human papillomavirus type 16 and 18 gene expression in cervical neoplasias.
        Hum Pathol. 1992; 23: 117-128
        • Vernon SD
        • Unger ER
        • Miller DL
        • Lee DR
        • Reeves WC
        Association of human papillomavirus type 16 integration in the E2 gene with poor disease-free survival from cervical cancer.
        Int J Cancer. 1997; 74: 50-56
        • Frattini MG
        • Lim HB
        • Laimins LA
        In vitro synthesis of oncogenic human papillomaviruses requires episomal genomes for differentiation-dependent late expression.
        Proc Natl Acad Sci USA. 1996; 93: 3062-3067